Citi Downgrades Auxilium Pharmaceuticals (AUXL) to Hold Citi downgrades Auxilium Pharmaceuticals Inc (Nasdaq: AUXL) from Buy to Hold.Price target lowered from $43 to $37.
Citi analyst says, 'We believe Auxilium's Xiaflex offers patients with Dupuytren's Contracture (DC) a non-invasive, safe...
Slate Pharmaceuticals raises $5 million CEO Bob Whitehead says the pellet, which is inserted just under the skin, provides an alternative way of replacing testosterone in older men who have low levels of the hormone.Right now, testosterone replacement is done by injection, skin...
Slate Pharmaceuticals raises $5 million CEO Bob Whitehead says the pellet, which is inserted just under the skin, provides an alternative way of replacing testosterone in older men who have low levels of the hormone.Right now, testosterone replacement is done by injection, skin...
Auxilium Pharmaceuticals to Announce Second Quarter 2008 Results and Conduct Conference Call on Thursday, July (Marketwire Via Acquire Media NewsEdge) MALVERN, PA, July 17 / MARKET WIRE/ -- Auxilium Pharmaceuticals, Inc.(NASDAQ: AUXL), a specialty biopharmaceutical company, will release results for the second quarter 2008 on Thursday, July 31,...
Auxilium Pharmaceuticals to Announce Second Quarter 2008 Results and Conduct Conference Call on Thursday, July MALVERN, PA -- (MARKET WIRE) -- 07/17/08 -- Auxilium Pharmaceuticals, Inc.(AUXL), a specialty biopharmaceutical company, will release results for the second quarter 2008 on Thursday, July 31, 2008 before the opening of the financial...
Auxilium Pharmaceuticals to Announce Second Quarter 2008 Results and Conduct Conference Call on Thursday, July LVERN, PA, July 17 / MARKET WIRE/ -- Auxilium Pharmaceuticals, Inc.(NASDAQ: AUXL), a specialty biopharmaceutical company, will release results for the second quarter 2008 on Thursday, July 31, 2008 before the opening of the financial...
Auxilium Pharmaceuticals, Inc.: Auxilium Pharmaceuticals to Announce Second Quarter 2008 Results and Conduct C - Auxilium Pharmaceuticals, Inc.(NASDAQ Mr.
Armando Anido, Chief Executive Officer and President, will host the conference call.
About Auxilium Auxilium Pharmaceuticals, Inc.
is a specialty biopharmaceutical company with a focus on...
Auxilium Pharmaceuticals to Announce Second Quarter 2008 Results and Conduct Conference Call on Thursday, July Auxilium Pharmaceuticals, Inc.(NASDAQ: AUXL), a specialty biopharmaceutical company, will release results for the second quarter 2008 on Thursday, July 31, 2008 before the opening of the financial markets.
The Company will also conduct...
Auxilium Pharmaceuticals to Announce Second Quarter 2008 Results and Conduct Conference Call on Thursday, July -- Auxilium Pharmaceuticals, Inc.(NasdaqGM:AUXL - News), a specialty biopharmaceutical company, will release results for the second quarter 2008 on Thursday, July 31, 2008 before the opening of the financial markets.
The Company will...
Auxilium Pharmaceuticals to Announce Second Quarter 2008 Results and Conduct Conference Call on Thursday, July - Auxilium Pharmaceuticals, Inc.(NASDAQ Mr.
Armando Anido, Chief Executive Officer and President, will host the conference call.
About Auxilium Auxilium Pharmaceuticals, Inc.
is a specialty biopharmaceutical company with a focus on...
CPEX Pharmaceuticals Shares to Begin Trading Today Following Spin-off from Bentley Pharmaceuticals EXETER, N.H.-- (BUSINESS WIRE) -- CPEX Pharmaceuticals, Inc.(NASDAQ: CPEX) completed its previously announced taxable spin-off from Bentley Pharmaceuticals, Inc.
(NYSE: BNT) yesterday at 11:59 p.m.
Shares of the new company will begin...
Premium Company Profile - Auxilium Pharmaceuticals - New Research Report on Companies and Markets Company-Profile/Premium-Comp ..Introduction Auxiliums main focus is to develop and commercialize products for the treatment of health problems in the areas of urology and sexual health.
The company has only one marketed product, ...
Repros initiates Phase IIb study of oral male fertility drug Enrollment of the 24 patients will commence at two sites in the New York City area shortly.All subjects will have been previously diagnosed with secondary hypogonadism and treated with topical testosterone for at least six months but not...
Repros Therapeutics Inc. Initiates a Comparative Phase 2b Study of Oral Androxal as Compared to Topical Testim - Repros Therapeutics Inc.(NasdaqGM:RPRX) reported today that the clinical sites have been initiated for its Phase 2b clinical study monitoring the effects of Repros' oral drug Androxal(R) on male fertility and testicular function in...
Repros Therapeutics Inc. Initiates a Comparative Phase 2b Study of Oral Androxal(R) as Compared to Topical Tes - Repros Therapeutics Inc.(NasdaqGM:RPRX) reported today that the clinical sites have been initiated for its Phase 2b clinical study monitoring the effects of Repros' oral drug Androxal(R) on male fertility and testicular function in...
CPEX Pharmaceuticals Shares to Begin Trading Today Following Spin-off from Bentley Pharmaceuticals Author : NH-CPEX/BENTLEY Category : Press Release News Alerts by Email click here ) News | Home EXETER, N.H.- (Business Wire) CPEX Pharmaceuticals, Inc.
(NASDAQ: CPEX) completed its previously announced taxable spin-off from Bentley...
CPEX Pharmaceuticals Shares to Begin Trading Today Following Stocks mentioned in this article Bentley Pharmaceuticals Inc (BNT) Stock Quote, Chart, News, Add to Watchlist CPEX Pharmaceuticals, Inc.CPEX completed its previously announced taxable spin-off from Bentley Pharmaceuticals, Inc.
BNT...
CPEX Pharmaceuticals Shares to Begin Trading Today Following Spin-off from Bentley Pharmaceuticals EXETER, N.H.--(BUSINESS WIRE)--CPEX Pharmaceuticals, Inc.(NASDAQ: CPEX - News) completed its previously announced taxable spin-off from Bentley Pharmaceuticals, Inc.
(NYSE: BNT - News) yesterday at 11:59 p.m.
Shares of the new company...
Repros Therapeutics Inc. Initiates a Comparative Phase 2b Study of Oral Androxal(R) as Compared to Topical Tes , 6:00 AM EST News source: Business Wire Repros Therapeutics Inc.(NasdaqGM:RPRX) reported today that the clinical sites have been initiated for its Phase 2b clinical study monitoring the effects of Repros' oral drug Androxal(R) on male...
Repros Therapeutics Inc. Initiates a Comparative Phase 2b Study of Oral Androxal as Compared to Topical Testim - Repros Therapeutics Inc.(NasdaqGM:RPRX) reported today that the clinical sites have been initiated for its Phase 2b clinical study monitoring the effects of Repros' oral drug Androxal(R) on male fertility and testicular function in...
Auxilium Pharmaceuticals (SkyNewswire.com)--MALVERN, PA--Auxilium Pharmaceuticals, Inc.(NASDAQ: AUXL) today announced that executive management will participate in the FBR Capital Markets 12th Annual Spring Investor Conference to be held May 28 - May 29, 2008 at...
Auxilium Pharmaceuticals, Inc.: Auxilium Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Con - Auxilium Pharmaceuticals, Inc.(NASDAQ To listen to the audio web cast of the presentation during or after the event, please visit: http://www.auxilium.com.
The replay will be available for ninety days after the event.
About Auxilium...
Auxilium Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference Auxilium Pharmaceuticals, Inc.(NASDAQ: AUXL) today announced that executive management will participate in the Jefferies 2nd Annual Healthcare Conference to be held June 24 - June 26, 2008 at The Mandarin Oriental in New York City.
Auxilium Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference -- Auxilium Pharmaceuticals, Inc.(NasdaqGM:AUXL - News) today announced that executive management will participate in the Jefferies 2nd Annual Healthcare Conference to be held June 24 - June 26, 2008 at The Mandarin Oriental in New York...
Auxilium Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference MALVERN, PA -- (MARKET WIRE) -- 06/18/08 -- Auxilium Pharmaceuticals, Inc.(NASDAQ: AUXL) today announced that executive management will participate in the Jefferies 2nd Annual Healthcare Conference to be held June 24 - June 26, 2008 at...
